Phaseline

Companies › Vericel

Vericel: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 3; Other; next expected readout Feb 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
autologous cultured chondrocytes on porcine collagen membrane (MACI)
autologous chondrocyte implantation on porcine collagen scaffold for cartilage repair
–Phase 3Chondral DefectFeb 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03588975autologous cultured chondrocytes on porcine collagen membrane (MACI)Phase 3Chondral DefectOtherFeb 2030
NCT06915233autologous cultured chondrocytes on porcine collagen membrane (MACI)Phase 3Chondral DefectOtherJul 2030

From the company's SEC filings

Cash and short-term investments of $170m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aesculap Biologics Metcela OHB Pediatrics CoNextions Medical ULURU

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.